Accessibility Menu
 
Summit Therapeutics logo

Summit Therapeutics

(NASDAQ) SMMT

Current Price$16.60
Market Cap$12.34B
Since IPO (2015)+61%
5 Year+205%
1 Year-20%
1 Month+6%

Summit Therapeutics Financials at a Glance

Market Cap

$12.34B

Revenue (TTM)

$0.00

Net Income (TTM)

$1.08B

EPS (TTM)

$-1.44

P/E Ratio

-11.48

Dividend

$0.00

Beta (Volatility)

0.97 (Low)

Price

$16.60

Volume

90,637

Open

$17.45

Previous Close

$16.60

Daily Range

$16.40 - $17.45

52-Week Range

$13.83 - $36.91

SMMT: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Summit Therapeutics

Industry

Biotechnology

Employees

265

CEO

Robert William Duggan; Mahkam Zanganeh, DDS, MBA

Headquarters

Cambridge, MA 02142, US

SMMT Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-206%

Return on Capital

-1%

Return on Assets

-1%

Earnings Yield

-8.71%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$12.34B

Shares Outstanding

744.44M

Volume

90.64K

Short Interest

0.00%

Avg. Volume

2.64M

Financials (TTM)

Gross Profit

$108.36K

Operating Income

$812.24M

EBITDA

$801.12M

Operating Cash Flow

$322.93M

Capital Expenditure

$657.00K

Free Cash Flow

$323.59M

Cash & ST Invst.

$713.45M

Total Debt

$15.50M

Summit Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$4.36K

+100.0%

Gross Margin

0.00%

N/A

Market Cap

$12.34B

N/A

Market Cap/Employee

$77.63M

N/A

Employees

159

N/A

Net Income

$219.17M

-258.1%

EBITDA

$59.08M

+196.6%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$697.94M

+72.3%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$12.99M

+276.2%

Short Term Debt

$2.51M

-33.2%

Return on Assets

-1.44%

N/A

Return on Invested Capital

-1.20%

N/A

Free Cash Flow

$100.16M

-105.7%

Operating Cash Flow

$100.00M

-105.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IONSIonis Pharmaceuticals, Inc.
$72.15-2.82%
UHSUniversal Health Services, Inc.
$184.04-0.57%
ASNDAscendis Pharma A/S
$216.95-1.65%
BBIOBridgeBio Pharma, Inc.
$69.70-3.97%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$38.78-0.06%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$8.28+0.05%
QQQInvesco QQQ Trust
$562.58-0.02%
ARTLArtelo Biosciences
$10.54+2.30%

Questions About SMMT

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.